Group 1 - Bio-Techne Corporation announced a quarterly dividend of $0.08 per share for the quarter ended June 30, 2024, payable on August 30, 2024, to shareholders of record on August 19, 2024 [1] - The company generated approximately $1.2 billion in net sales in fiscal 2024 and has around 3,100 employees globally [2] - Bio-Techne provides innovative tools and bioactive reagents for research and clinical diagnostics, aiding in drug discovery and accurate clinical tests [2] Group 2 - The Board of Directors will consider future cash dividends on a quarterly basis [1] - The company has a diverse portfolio with thousands of products that assist in scientific investigations into biological processes and diseases [2] - Bio-Techne's operations may be influenced by various factors including market competition, economic conditions, and research funding [3]

MINNEAPOLIS, July 31, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) is pleased to announce the launch of the Leo™ System. This next-generation Simple Western™ instrument offers higher throughput, flexibility, and efficiency over the current Jess™ and Abby™ Simple Western Systems. This stateof-the-art instrument enables simultaneous processing of up to 100 samples in a single 3-hour run, allowing scientists to process more samples in a day. Leo also provides 4-times the experimental size of Jess ...

MINNEAPOLIS, July 29, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced its participation in Spear Bio's $45 million Series A funding round. Spear Bio will use the proceeds from this funding round to further accelerate product development and scale its in-house manufacturing capacity. BioTechne joined Foresite Capital, and other investors, in this funding round. Founded in 2021 and headquartered in Woburn, Massachusetts, Spear Bio is an innovative leader in the development, and manu ...

Core Viewpoint - Oddity Tech Ltd. and certain executives are facing charges for failing to disclose material information during the Class Period, which is a violation of federal securities laws [1]. Group 1: Legal Proceedings - Investors have until September 17, 2024, to file lead plaintiff applications in a securities class action lawsuit against Oddity, covering purchases made between July 19, 2023, and May 20, 2024 [2]. - The lawsuit is currently pending in the United States District Court for the Eastern District of New York [2]. - The case is identified as Hoare v. Oddity Tech Ltd., et al., 24-cv-05037 [5]. Group 2: Allegations Against Oddity - NINGI Research reported multiple allegations against Oddity, claiming the company misled investors about critical aspects of its business [4]. - Allegations include that Oddity's AI is merely a questionnaire and that its reported "repeat purchase rates" are due to customers unknowingly entering non-cancelable plans [4]. - NINGI also found numerous undisclosed lawsuits against Oddity and its subsidiaries in the US and Israel, often related to unpaid bills and consumer protection law violations [4]. Group 3: Market Reaction - Following the news of the allegations, Oddity's share price dropped by $3.02, or 7.37%, closing at $37.97 per share on May 21, 2024 [7].

NEW ORLEANS, July 23, 2024 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 17, 2024 to file lead plaintiff applications in a securities class action lawsuit against ODDITY Tech Ltd. ("Oddity" or the "Company") (NasdaqGM: ODD), if they purchased the Company's securities between July 19, 2023 and May 20, 2024, inclusive (the "Class Period"). This action is pending in the United State ...

Click here to participate in the action. If you purchased or otherwise acquired Oddity Tech shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you ...

These are just a few of the metrics contributing to GMAB's Value grade of B and TECH's Value grade of D. There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits. Value investors also tend to look at a n ...

Core Viewpoint - Genmab A/S Sponsored ADR (GMAB) is currently viewed as a better value opportunity compared to Techne (TECH) based on various valuation metrics and earnings outlook [1][6]. Valuation Metrics - GMAB has a P/B ratio of 3.57, while TECH has a higher P/B of 5.57, indicating GMAB is more undervalued relative to its book value [3]. - The forward P/E ratio for GMAB is 23.03, significantly lower than TECH's forward P/E of 34.71, suggesting GMAB is more attractively priced [5]. - GMAB's PEG ratio stands at 0.93, which is favorable compared to TECH's PEG ratio of 6.51, indicating better expected earnings growth relative to its price [5]. Earnings Outlook - GMAB holds a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while TECH has a Zacks Rank of 3 (Hold), suggesting a less favorable earnings forecast [4]. - The positive earnings estimate revisions for GMAB further support its superior position in terms of earnings outlook compared to TECH [4][6]. Value Grades - GMAB has received a Value grade of B, reflecting its strong valuation metrics, while TECH has a Value grade of D, indicating weaker valuation characteristics [9].

CETI's focus is to treat and repurpose a substantial amount of the water it receives from oil fields. Posttreatment, this water can be reused by oil companies, in agriculture, or even as drinking water where needed. Globally, agriculture consumes about 70% of freshwater resources, making CETI's water remediation capabilities particularly valuable to local communities and Industries. ABOUT CYBER ENVIRO-TECH, INC. CETI is an international eco-conscious, oil/sludge, water and soil remediation Company. Using bi ...

Core Insights - CETI has developed proprietary products and systems that utilize environmentally friendly biologics, eliminating the need for chemical inputs and reducing operational costs and initial capital outlay [1] - CETI's water remediation approach achieves 100% removal efficiency, significantly outperforming traditional methods which only achieve approximately 43% removal, or 66% with additional chemicals [1] - The company addresses growing water contamination issues, particularly in potable water supplies, and aims to provide cost-effective, chemical-free remediation solutions that meet strict EPA standards [2] Company Overview - Cyber Enviro-Tech, Inc. (CETI) specializes in oil/sludge, water, and soil remediation using bio remedial materials and proprietary technologies [2] - CETI's core business model focuses on cleaning oil/sludge ponds, storage tanks, oil spills, mining, and other soil remediation projects, as well as contaminated industrial wastewater [2] - The company incorporates advanced technologies such as machine learning, artificial intelligence, and cloud computing into its remediation systems [2] Industry Context - Agriculture accounts for approximately 70% of global water consumption, and runoff from farms can severely impact potable water quality due to the presence of difficult-to-remediate chemicals [5] - CETI is currently in discussions and testing with potential clients in industries such as mining, oil and gas, agriculture, and meat processing, which are subject to strict government regulations [6] - The US government has recently finalized its first national drinking water standard, indicating an increase in regulatory scrutiny in the industry [6]